Yokoyama Takanori, Takehara Kazuhiro, Yamamoto Yasuko, Okame Shinichi, Shiroyama Yuko, Yokoyama Takashi, Nogawa Takayoshi, Sugawara Yosifumi
Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, Matsuyama, 791-0280, Japan.
Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, Matsuyama, 791-0280, Japan.
Int J Clin Oncol. 2015 Oct;20(5):960-6. doi: 10.1007/s10147-015-0800-0. Epub 2015 Feb 15.
The present study investigates the usefulness of 18F-FDG-PET/CT (PET/CT) in distinguishing between benign and malignant ovarian teratomas.
This study includes 4 mature teratomas (MTs) with malignant transformation, 8 immature teratomas (ITs), and 16 MTs that were diagnosed after surgical resection. Preoperative tumor marker values, MRI findings, PET/CT SUVmax values, and other clinical parameters were retrospectively compared with those of 14 patients who had MTs.
The median CA125 was significantly higher for ITs than for MTs (P = 0.04). The median AFP was significantly higher for ITs than for MTs (P = 0.0034). The median SUVmax values for MTs with malignant transformation, ITs, and MTs were 18.3 (5.3-23.3), 6.0 (3.6-22.6), and 1.1 (1.0-15.5), respectively. SUVmax was significantly higher in MTs with malignant transformation and ITs than in MTs (P = 0.004, P = 0.0007). With a cut-off SUVmax of 3.6 to distinguish between benign and malignant MTs, sensitivity was 100 %, specificity was 81 %, positive predictive value was 80 %, negative predictive value was 100 %, and diagnostic accuracy was 89 % (AUC 0.94). However, one patient with an MT had a high SUVmax corresponding to values in the central nervous system (CNS).
18F-FDG-PET/CT has a high diagnostic accuracy in distinguishing between benign and malignant ovarian teratomas. Thus, PET/CT may be useful in cases where the diagnosis is unclear on MRI and other clinical findings. However, some MTs with abundant CNS tissue may have a high SUVmax. Therefore, the diagnosis of a benign or malignant lesion should be made carefully in conjunction with other clinical findings.
本研究旨在探讨18F-FDG-PET/CT在鉴别卵巢良性和恶性畸胎瘤中的应用价值。
本研究纳入4例发生恶变的成熟畸胎瘤(MTs)、8例未成熟畸胎瘤(ITs)以及16例经手术切除后确诊的MTs。回顾性比较术前肿瘤标志物值、MRI表现、PET/CT的SUVmax值及其他临床参数与14例MTs患者的相关数据。
ITs患者的CA125中位数显著高于MTs患者(P = 0.04)。ITs患者的AFP中位数显著高于MTs患者(P = 0.0034)。发生恶变的MTs、ITs和MTs的SUVmax中位数分别为18.3(5.3 - 23.3)、6.0(3.6 - 22.6)和1.1(1.0 - 15.5)。发生恶变的MTs和ITs的SUVmax显著高于MTs(P = 0.004,P = 0.0007)。以SUVmax 3.6为界区分良性和恶性MTs,敏感性为100%,特异性为81%,阳性预测值为80%,阴性预测值为100%,诊断准确性为89%(AUC 0.94)。然而,1例MT患者的SUVmax较高,对应于中枢神经系统(CNS)的值。
18F-FDG-PET/CT在鉴别卵巢良性和恶性畸胎瘤方面具有较高的诊断准确性。因此,在MRI及其他临床检查结果诊断不明确的情况下,PET/CT可能有用。然而,一些含有丰富CNS组织的MTs可能具有较高的SUVmax。因此,应结合其他临床检查结果谨慎做出良性或恶性病变的诊断。